Assessment of Three Therapeutic Procedures in the Prevention of Diabetic Macular Oedema after Phacoemulsification through Intraocular Lens Implementation
DOI:
https://doi.org/10.6000/2292-2598.2020.08.02.20Keywords:
Diabetic macular oedema, Diabetic retinopathy, Bevacizumab, Diclofenac, Triamcinolone.Abstract
A cataract is an ocular complication of diabetes mellitus, and the risk of developing diabetic macular oedema (DME) increases in cataract surgery. This randomized, single-blind clinical trial study was conducted on 45 eyes (39 patients) with stable diabetic retinopathy with cataract to compare the efficacy of three therapeutic procedures in the prevention of DME after phacoemulsification through intraocular lens implantation. After cataract surgery by phacoemulsification, the patients were randomly assigned into three groups. The group A received 1.25 mg of intravitreal bevacizumab, and group B received a sub-tenon injection of 40 mg triamcinolone at the end of the surgery. The group C received topical diclofenac drops every 8h for four weeks after the surgery. Results showed there was no significant difference in the demographics and clinical features, central macular thickness, and systemic condition of the three groups at the beginning of the study. There was a significant difference between the preoperative and postoperative periods (i.e., three months after surgery) in the three groups regarding mean macular thickness; however, the difference among the three groups was not significant in the post-operative periods. The DME after cataract surgery occurred in 4 eyes (26.67%) in the diclofenac group and three eyes (20.00%) in the intravitreal bevacizumab and three eyes (20.00%) in sub-tenon triamcinolone groups. According to results, the administration of these three therapeutic procedures can be beneficial in the prevention of DME in patients with cataract and diabetic retinopathy.
References
Gallego-Pinazo R, Dolz-Marco R, Berrocal M, Wu L, Maia M, Serrano M, et al. Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group. Arq Bras Oftalmol 2014; 77(6): 355-9. https://doi.org/10.5935/0004-2749.20140089 DOI: https://doi.org/10.5935/0004-2749.20140089
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116(3): 497-503. https://doi.org/10.1016/j.ophtha.2008.10.016 DOI: https://doi.org/10.1016/j.ophtha.2008.10.016
Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010; 88(3): 279-91. https://doi.org/10.1111/j.1755-3768.2008.01501.x DOI: https://doi.org/10.1111/j.1755-3768.2008.01501.x
Hegazy SM, EL-Sada MA, EL-Malt M, EL-Agha M. Intravitreal Diclofenac Versus Intravitreal Triamcinolone for Diabetic Macular Edema. Med J Cairo Univ 2015; 83(2): 95-100.
Querques G, Bux AV, Martinelli D, Iaculli C, Del Curatolo MV, Delle Noci N. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. Retina (Philadelphia, Pa) 2009; 29(9): 1274-81. https://doi.org/10.1097/IAE.0b013e3181aa8e50 DOI: https://doi.org/10.1097/IAE.0b013e3181aa8e50
Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117(11): 2146-51. https://doi.org/10.1016/j.ophtha.2010.08.016 DOI: https://doi.org/10.1016/j.ophtha.2010.08.016
Mathew C, Yunirakasiwi A, Sanja S. Updates in the Management of Diabetic Macular Edema. Journal of Diabetes Research 2015; Article ID 794036, 8 pages. https://doi.org/10.1155/2015/794036 DOI: https://doi.org/10.1155/2015/794036
McLeod DS, Lutty GA. High-resolution histologic analysis of the human choroidal vasculature. Investigative Ophthalmology and Visual Science 1994; 35: 3799.
Wielders LHP, Schouten JSAG, Nuijts RMMA. Prevention of macular edema after cataract surgery. Curr Opin Ophthalmol 2018; 29(1): 48-53. https://doi.org/10.1097/ICU.0000000000000436 DOI: https://doi.org/10.1097/ICU.0000000000000436
Chung J, Kim MY, Kim HS, Yoo JS, Lee YC. Effect of cataract surgery on the progression of diabetic retinopathy. Journal of Cataract and Refractive Surgery 2002; 28(4): 626-30. https://doi.org/10.1016/S0886-3350(01)01142-7 DOI: https://doi.org/10.1016/S0886-3350(01)01142-7
Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Archives of ophthalmology (Chicago, III: 1960) 2006; 124(5): 653-8. https://doi.org/10.1001/archopht.124.5.653 DOI: https://doi.org/10.1001/archopht.124.5.653
Brito PN, Rosas VM, Coentrao LM, Carneiro AV, Rocha-Sousa A, Brandao E, et al. Evaluation of visual acuity, macular status, and subfoveal choroidal thickness changes after cataract surgery in eyes with diabetic retinopathy 2015; 35(2): 294-302. https://doi.org/10.1097/IAE.0000000000000298 DOI: https://doi.org/10.1097/IAE.0000000000000298
Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Lai WW, et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye (London, England) 2005; 19(8): 885-90. https://doi.org/10.1038/sj.eye.6701686 DOI: https://doi.org/10.1038/sj.eye.6701686
Faghihi H, Yahyapour H, Mahmoudzadeh R, Faghihi S. Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. Med Hypothesis Discov Innov Ophthalmol 2017; 6(3): 67-75.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109(5): 920-7. https://doi.org/10.1016/S0161-6420(02)00975-2 DOI: https://doi.org/10.1016/S0161-6420(02)00975-2
Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112(11): 1916-20. https://doi.org/10.1016/j.ophtha.2005.06.009 DOI: https://doi.org/10.1016/j.ophtha.2005.06.009
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9): 999-1005. https://doi.org/10.1097/01.iae.0000247165.38655.bf DOI: https://doi.org/10.1097/01.iae.0000247165.38655.bf
Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. The Annals of Pharmacotherapy 2007; 41(4): 614-25. https://doi.org/10.1345/aph.1H316 DOI: https://doi.org/10.1345/aph.1H316
Lee SJ, Kim ET, Moon YS. Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema. Korean Journal of Ophthalmology: KJO 2011; 25(5): 299-304. https://doi.org/10.3341/kjo.2011.25.5.299 DOI: https://doi.org/10.3341/kjo.2011.25.5.299
Arevalo JF. Diabetic macular edema: Current management 2013. World J Diabetes 2013; 4(6): 231-3. https://doi.org/10.4239/wjd.v4.i6.231 DOI: https://doi.org/10.4239/wjd.v4.i6.231
Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, Battaglia Parodi M. Pharmacological approach to diabetic macular edema. Ophthalmic Res 2014; 51(2): 88-95. https://doi.org/10.1159/000356693 DOI: https://doi.org/10.1159/000356693
Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cyclooxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10(27): 3331-48. https://doi.org/10.2174/1381612043383142 DOI: https://doi.org/10.2174/1381612043383142
Akinci A, Muftuoglu O, Altinsoy A, Ozkilic E. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Retina (Philadelphia, Pa) 2011; 31(4): 755-8. https://doi.org/10.1097/IAE.0b013e3182006da1 DOI: https://doi.org/10.1097/IAE.0b013e3182006da1
Ozgur OR, Ozkurt Y, Kulekci Z, Evciman T. The combination of phacoemulsification surgery and intravitreal triamcinolone injection in patients with cataract and diabetic macular edema. Saudi J Ophthalmol 2016; 30(1): 33-38. https://doi.org/10.1016/j.sjopt.2015.10.004 DOI: https://doi.org/10.1016/j.sjopt.2015.10.004
Chae JB, Joe SG, Yang SJ, Lee JY, Sung KR, Kim JY, Kim JG, Yoon YH. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina 2014; 34(1): 149-56. https://doi.org/10.1097/IAE.0b013e3182979b9e DOI: https://doi.org/10.1097/IAE.0b013e3182979b9e
Ibrahim MA, Sepah YJ, Symons RCA, Channa R, Hatef E, Khwaja A. et al. Spectral- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye 2012; 26: 454-462. https://doi.org/10.1038/eye.2011.293 DOI: https://doi.org/10.1038/eye.2011.293
Grover S, Murthy RK, Brar VS, Chalam KV. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 2009; 148(2): 266-271. https://doi.org/10.1016/j.ajo.2009.03.006 DOI: https://doi.org/10.1016/j.ajo.2009.03.006
Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007; 114(5): 881-9. https://doi.org/10.1016/j.ophtha.2006.08.053 DOI: https://doi.org/10.1016/j.ophtha.2006.08.053
Fard MA, Yazdanei Abyane A, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study. Eur J Ophthalmol 2011; 21(3): 276-81. https://doi.org/10.5301/EJO.2010.1405 DOI: https://doi.org/10.5301/EJO.2010.1405
Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010; 30(3): 509-15. https://doi.org/10.1097/IAE.0b013e3181bdfa43 DOI: https://doi.org/10.1097/IAE.0b013e3181bdfa43
Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, et al. Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 2015; 35(3): 421-8. https://doi.org/10.1007/s10792-014-9967-z DOI: https://doi.org/10.1007/s10792-014-9967-z
Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina 2009; 29(4): 530-5. https://doi.org/10.1097/IAE.0b013e31819c6302 DOI: https://doi.org/10.1097/IAE.0b013e31819c6302
Rauen PI, Ribeiro JA, Almeida FP, Scott IU, Messias A, Jorge R Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina 2012; 32(9): 1799-803. https://doi.org/10.1097/IAE.0b013e31824bebb8 DOI: https://doi.org/10.1097/IAE.0b013e31824bebb8
Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 2011; 31(10): 2058-64. https://doi.org/10.1097/IAE.0b013e31822a042a DOI: https://doi.org/10.1097/IAE.0b013e31822a042a
Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: Prospective randomized study. J Cataract Refract Surg 2009; 35: 18-25. https://doi.org/10.1016/j.jcrs.2008.09.019 DOI: https://doi.org/10.1016/j.jcrs.2008.09.019
Salehi A, Beni AN, Razmjoo H, Beni ZN. Phacoemulsification with intravitreal bevacizumab injection in patients with cataract and coexisting diabetic retinopathy: prospective randomized study. J Ocul Pharmacol Ther 2012; 28(3): 212-8. https://doi.org/10.1089/jop.2011.0069 DOI: https://doi.org/10.1089/jop.2011.0069
Downloads
Published
How to Cite
Issue
Section
